[NMusers] Advanced PK/PD & Pop PK Modeling Training in Princeton, NJ

From: Andre Keller <Andre.Keller_at_certara.com>
Date: Mon, 13 Apr 2015 18:44:57 +0000

Dear Members,

Are you an experienced PK/PD modeling scientist ready to take your skills t=
o the next level? Then you are invited to join Dr. Daniel Weiner for the 17=
th Advanced Level Workshop on Pharmacokinetic-Pharmacodynamic Data Analysis=
 in Princeton, NJ. Register today and receive a 20% discount! (expires June=

17th Advanced Level Workshop on Pharmacokinetic - Pharmacodynamic Data Anal=

August 17-20, 2015

Princeton, NJ

Register Here: https://www.certara.com/training/classes/105

Learn to apply advanced approaches for conducting PK/PD analysis. This cour=
se aims to give the course participants confidence and encouragement to hav=
e a go at PK/PD and to practice PK/PD data analysis on real life case studi=
es from discovery, preclinical and development. The program is comprised o=
f lectures and group exercises with discussion, combined with hands-on PK/=
PD data analysis sessions. Lectures will cover many topics including experi=
mental design, target mediated drug disposition, instantaneous and delayed =
drug responses, effect-compartment, turnover and binding models, functional=
 adaptation, transduction, mixture dynamics, drug-combination pd, pattern r=
ecognition, pop pk and translational aspects of PK and PD.

Who should attend?

Scientists with at least five years of experience in PK/PD modeling. Qualif=
ied graduate students.

Topics include:

Dose-response-time analysis, advanced principles of turnover modeling inclu=
ding modeling tolerance and rebound, approaches to TMDD modeling, approache=
s to optimizing sampling collection times, modeling PD effects for combinat=
ion drug treatments, pattern recognition, and translational aspects of PK/P=
D modeling.

Daniel Weiner Ph.D.

Dr. Weiner has extensive drug development experience and has served as an e=
xpert consultant to the U.S. Food and Drug Administration (FDA) on pharmaco=
kinetic modeling and bioequivalence assessment. Prior to his previous tenur=
e with Pharsight as a Senior Vice President, Dr. Weiner held several manage=
ment positions including Head, Biostatistics, Merrell Dow Pharmaceuticals; =
Vice President, Statistical Consultants, Inc.; Vice President, Syntex Devel=
opment Research; Senior Vice President and Principal Scientist, Quintiles, =
and most recently, Senior Vice President and Global Head of Clinical Develo=
pment at IVAX Research.

Andre Keller
5520 Dillard Dr., Suite 260
Cary, NC 27518
Tel +1-919-852-4611
www.certara.com<http://www.certara.com/> NOTICE: The information co=
ntained in this electronic mail message is intended only for the personal a=
nd confidential use of the designated recipient(s) named above. This m=
essage may be an attorney-client communication, may be protected by th=
e work product doctrine, and may be subject to a protective order. As such,=
 this message is privileged and confidential. If the reader of this me=
ssage is not the intended recipient or an agent responsible for delivering =
it to the intended recipient, you are hereby notified that you have re=
ceived this message in error and that any review, dissemination, distr=
ibution, or copying of this message is strictly prohibited. If you have rec=
eived this communication in error, please notify us immediately by tel=
ephone and e-mail and destroy any and all copies of this message in yo=
ur possession (whether hard copies or electronically stored copies). Thank =
you. buSp9xeMeKEbrUze

Received on Mon Apr 13 2015 - 14:44:57 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:43:52 EDT